Amgen (AMGN) Stock Dividend Data

Amount	Ex-Dividend Date	Record Date	Pay Date	Declare Date	Qualified? [?]	Type
$0.47	5/14/2013	5/16/2013	6/7/2013	3/6/2013	Yes	Regular
$0.47	2/11/2013	2/13/2013	3/7/2013	12/13/2012	Yes	Regular
$0.36	11/13/2012	11/15/2012	12/7/2012	10/11/2012	Yes	Regular
$0.36	8/14/2012	8/16/2012	9/7/2012	7/19/2012	Yes	Regular

AMGN has been increasing its dividend at least once per year since 2011.

Only for Premium Members

If you were a Dividend.com Premium member, you would be seeing detailed DARS™ Dividend Stock Ratings information for Amgen (AMGN) in this space, including whether we think your should Buy, Hold, or Sell this stock.

Sign up for Dividend.com Premium today to gain access to ratings on nearly 1,600 dividend-paying stocks, exclusive members-only articles, historical dividend information, and more!

Subscribe to Dividend.com Premium Today! »

Amgen (AMGN) - this company discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.